Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | HTR2B | P41595 | 2/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24353419 | 0.82 | HTR2C (0.36) | HTR2CHTR2BCTSKALDH1A1TSHR | |
| SCHEMBL23748190 | 0.81 | HTR2C (0.33) | HTR2CHTR2BFFAR1ALDH1A1TP53 | |
| SCHEMBL28612754 | 0.80 | HTR2C (0.35) | HTR2CHTR2B | |
| SCHEMBL23748156 | 0.80 | MAPT (0.36) | HTR2CHTR2BSQORCHRNB2CHRNB4 | |
| SCHEMBL23856052 | 0.80 | HTR2C (0.31) | HTR2CHTR2B | |
| SCHEMBL28631801 | 0.79 | HTR2C (0.37) | HTR2CHTR2BALDH1A1 | |
| SCHEMBL28629203 | 0.79 | HTR2C (0.37) | HTR2CHTR2B | |
| SCHEMBL23748242 | 0.78 | L3MBTL1 (0.41) | HTR2CHTR2BSQORALDH1A1TSHR | |
| SCHEMBL28617668 | 0.78 | HTR2C (0.34) | HTR2CHTR2BL3MBTL1 | |
| SCHEMBL23748244 | 0.77 | TSHR (0.39) | CHRNB2CHRNB4CHRNA3CHRNA4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002409-A1 | MACROCYCLIC FLU ENDONUCLEASE INHIBITORS | JANSSEN BIOPHARMA INC (US) | 2023-01-05 | — | — | US | disclosed |
| US-11312727-B1 | Macrocyclic flu endonuclease inhibitors | Janssen Biopharma, Inc. (US) | 2022-04-26 | — | — | US | disclosed |
| EP-3864020-A1 | MACROCYCLIC FLU ENDONUCLEASE INHIBITORS | Janssen BioPharma, Inc. (US) | 2021-08-18 | — | — | EP | disclosed |
| CN-113195502-A | Macrocyclic influenza endonuclease inhibitors | 詹森生物制药有限公司 | 2021-07-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002409-A1 | MACROCYCLIC FLU ENDONUCLEASE INHIBITORS | ACE, PNP, FEN1 | HTR2C 2220/4885HTR2B 3558/4885CTSK 490/4885 |
| US-11312727-B1 | Macrocyclic flu endonuclease inhibitors | ACE, FEN1, PNP | HTR2C 2792/4885HTR2B 3691/4885CTSK 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.